Genmab A/S (NASDAQ:GMAB) and Alaunos Therapeutics (NASDAQ:TCRT) Financial Survey
Genmab A/S (NASDAQ:GMAB) and Alaunos Therapeutics (NASDAQ:TCRT) Financial Survey
Alaunos Therapeutics (NASDAQ:TCRT – Get Rating) and Genmab A/S (NASDAQ:GMAB – Get Rating) are both medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, dividends, institutional ownership, valuation, earnings, risk and analyst recommendations.
纳斯达克(代码：TCRT-GET Rating)和基因泰克A/S(纳斯达克代码：GMAB-GET Rating)都是医疗公司，但哪一项投资更具优势？我们将根据这两家公司的盈利能力、股息、机构所有权、估值、收益、风险和分析师建议的强弱对它们进行比较。
Valuation & Earnings
估值与收益
This table compares Alaunos Therapeutics and Genmab A/S's gross revenue, earnings per share (EPS) and valuation.
下表比较了ALaunos Treateutics和Genmab A/S的毛收入、每股收益(EPS)和估值。
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Alaunos Therapeutics | $400,000.00 | 350.81 | -$78.75 million | ($0.19) | -3.42 |
| Genmab A/S | $1.35 billion | 20.72 | $478.57 million | $1.22 | 34.74 |
| 总收入 | 价格/销售额比 | 净收入 | 每股收益 | 市盈率 | |
| ALaunos治疗公司 | $400,000.00 | 350.81 | -7,875万元 | ($0.19) | -3.42 |
| Genmab A/S | 13.5亿美元 | 20.72 | 4.7857亿美元 | $1.22 | 34.74 |
Genmab A/S has higher revenue and earnings than Alaunos Therapeutics. Alaunos Therapeutics is trading at a lower price-to-earnings ratio than Genmab A/S, indicating that it is currently the more affordable of the two stocks.
Genmab A/S的收入和收益高于ALaunos治疗公司。ALaunos治疗公司的市盈率低于Genmab A/S，这表明它目前是两只股票中更负担得起的一只。
Profitability
盈利能力
| Net Margins | Return on Equity | Return on Assets | |
| Alaunos Therapeutics | N/A | -88.31% | -49.35% |
| Genmab A/S | 46.32% | 22.78% | 20.33% |
| 净利润率 | 股本回报率 | 资产回报率 | |
| ALaunos治疗公司 | 不适用 | -88.31% | -49.35% |
| Genmab A/S | 46.32% | 22.78% | 20.33% |
Analyst Ratings
分析师评级
This is a breakdown of recent ratings and recommmendations for Alaunos Therapeutics and Genmab A/S, as provided by MarketBeat.com.
这是MarketBeat.com提供的ALaunos治疗公司和Genmab A/S公司最近的评级和推荐细目。
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Alaunos Therapeutics | 0 | 2 | 2 | 0 | 2.50 |
| Genmab A/S | 2 | 11 | 3 | 0 | 2.06 |
| 销售评级 | 保持评级 | 购买评级 | 强劲的买入评级 | 评级分数 | |
| ALaunos治疗公司 | 0 | 2 | 2 | 0 | 2.50 |
| Genmab A/S | 2 | 11 | 3 | 0 | 2.06 |
Alaunos Therapeutics currently has a consensus target price of $2.50, indicating a potential upside of 285.15%. Genmab A/S has a consensus target price of $38.55, indicating a potential downside of 9.05%. Given Alaunos Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Alaunos Therapeutics is more favorable than Genmab A/S.
ALaunos治疗公司目前的共识目标价为2.5美元，表明潜在上涨285.15%。Genmab A/S的共识目标价为38.55美元，表明潜在下行9.05%。鉴于ALaunos治疗公司更高的共识评级和更高的可能上行空间，分析师们显然认为ALaunos治疗公司比Genmab A/S更有利。
Risk & Volatility
风险与波动性
Alaunos Therapeutics has a beta of 0.07, suggesting that its stock price is 93% less volatile than the S&P 500. Comparatively, Genmab A/S has a beta of 0.99, suggesting that its stock price is 1% less volatile than the S&P 500.
ALaunos治疗公司的贝塔系数为0.07，这表明其股价的波动性比标准普尔500指数低93%。相比之下，Genmab A/S的贝塔系数为0.99，这表明其股价的波动性比标准普尔500指数低1%。
Institutional & Insider Ownership
机构与内部人持股
34.4% of Alaunos Therapeutics shares are owned by institutional investors. Comparatively, 6.7% of Genmab A/S shares are owned by institutional investors. 4.9% of Alaunos Therapeutics shares are owned by company insiders. Comparatively, 1.5% of Genmab A/S shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.
ALaunos治疗公司34.4%的股份由机构投资者持有。相比之下，Genmab A/S公司6.7%的股份由机构投资者持有。ALaunos治疗公司4.9%的股份由公司内部人士持有。相比之下，Genmab A/S公司1.5%的股份由公司内部人士持有。强大的机构持股表明，捐赠基金、对冲基金和大型基金管理公司相信，一只股票有望实现长期增长。
Summary
摘要
Genmab A/S beats Alaunos Therapeutics on 9 of the 14 factors compared between the two stocks.
Genmab A/S在两只股票之间比较的14个因素中有9个击败了ALaunos Treateutics。
About Alaunos Therapeutics
ALaunos治疗公司简介
(Get Rating)
(获取评级)
Alaunos Therapeutics, Inc., a clinical-stage oncology-focused cell therapy company, develops adoptive TCR engineered T-cell therapies. It develops TCR Library, which is in Phase I/II clinical trial for ten TCRs reactive to mutated KRAS, TP53, and EGFR from its TCR library for the treatment of non-small cell lung, colorectal, endometrial, pancreatic, ovarian, and bile duct cancers; hunTR, a human neoantigen T-cell receptor platform; and mbIL-15 to treat solid tumors. Alaunos Therapeutics, Inc. has a license agreement with PGEN Therapeutics, Inc.; research and development agreement with The University of Texas MD Anderson Cancer Center; and a patent license agreement, and research and development agreement with the National Cancer Institute. The company was formerly known as ZIOPHARM Oncology, Inc. and changed its name to Alaunos Therapeutics, Inc. in January 2022. Alaunos Therapeutics, Inc. is headquartered in Houston, Texas.
ALaunos治疗公司是一家专注于临床阶段肿瘤学的细胞治疗公司，开发采用TCR工程的T细胞疗法。该公司开发了TCR文库，该文库对10个对突变的KRAS、TP53和EGFR产生反应的TCR进行了I/II期临床试验，这些TCR文库用于治疗非小细胞肺癌、结直肠癌、子宫内膜癌、胰腺癌、卵巢癌和胆管癌；人类肿瘤抗原T细胞受体平台HunTR；以及用于治疗实体肿瘤的MBIL-15。ALaunos治疗公司与PGEN治疗公司签订了许可协议；与德克萨斯大学MD安德森癌症中心签订了研发协议；与美国国家癌症研究所签订了专利许可协议和研发协议。该公司前身为ZIOPHARM肿瘤学公司，并于2022年1月更名为ALaunos治疗公司。ALaunos治疗公司总部设在得克萨斯州休斯敦。
About Genmab A/S
关于Genmab A/S
(Get Rating)
(获取评级)
Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; ofatumurnab, a human monoclonal antibody to treat chronic lymphocytic leukemia (CLL) and multiple sclerosis; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC. Its products include daratumumab to treat MM, non-MM blood cancers, and AL amyloidosis; GEN1047; tisotumab vedotin for treating cervical, ovarian, and solid cancers; DuoBody-PD-L1x4-1BB, and DuoBody-CD40x4-1BB for treating solid tumors; Epcoritamab for relapsed/refractory diffuse large B-cell lymphoma and chronic lymphocytic leukemia; and HexaBody-CD38 and DuoHexaBody-CD37 for treating hematological malignancies. The company's also develops products, which is in Phase 2 comprise Teclistamab for vaso-occlusive crises; Camidanlumab tesirine to treat hodgkin lymphoma and solid tumors; JNJ-64007957 and JNJ-64407564 to treat MM; PRV-015 for treating celiac disease; Mim8 for treating haemophilia A; and Lu AF82422 for treating multiple system atrophy disease. In addition, it has approximately 20 active pre-clinical programs. The company has a commercial license and collaboration agreement with Seagen Inc. to co-develop tisotumab vedotin. It also has a collaboration agreement with CureVac AG for the research and development of differentiated mRNA-based antibody products; AbbVie for the development of epcoritamab; and collaborations with BioNTech, Janssen, Novo Nordisk A/S, BliNK Biomedical SAS, and Bolt Biotherapeutics, Inc. Genmab A/S was founded in 1999 and is headquartered in Copenhagen, Denmark.
Genmab A/S主要在丹麦开发用于治疗癌症和其他疾病的抗体疗法。该公司销售用于治疗多发性骨髓瘤(MM)患者的人类单抗DARZALEX；用于治疗甲状腺眼病的teprotomumab；用于治疗慢性淋巴细胞白血病(CLL)和多发性硬化症的人类单抗Ofatumurnab；以及用于晚期或转移性胃癌、食道癌和非小细胞肺癌的Amivantamab。其产品包括用于治疗MM、非MM血癌和AL淀粉样变性的daratumab；GEN1047；用于治疗宫颈癌、卵巢癌和实体瘤的tisotomab vedotin；用于治疗实体瘤的DuoBody-PD-L1x4-1BB和DuoBody-CD40x4-1BB；用于复发/难治性弥漫性大B细胞淋巴瘤和慢性淋巴细胞白血病的Epcoritamab；以及用于治疗血液系统恶性肿瘤的HexaBody-CD38和DuoHexaBody-CD37。该公司还开发处于第二阶段的产品，包括用于血管闭塞危机的Tecistamab；用于治疗霍奇金淋巴瘤和实体瘤的CamidanLumab Tesiine；用于治疗MM的JNJ-64007957和JNJ-64407564；用于治疗乳糜泻的PRV-015；用于治疗血友病A的MIM8；以及用于治疗多系统萎缩性疾病的Lu AF82422。此外，它还有大约20个活跃的临床前项目。该公司与Seagen Inc.有商业许可和合作协议，共同开发tisotomab vedotin。它还与CureVac AG签订了研究和开发不同的基于信使核糖核酸的抗体产品的合作协议；AbbVie公司开发epcoritamab；与BioNTech公司、Janssen公司、Novo Nordisk A/S公司、Blink Biomedical SAS公司和Bolt BioTreateutics公司合作。Genmab A/S公司成立于1999年，总部设在丹麦哥本哈根。
Receive News & Ratings for Alaunos Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alaunos Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
接受ALaunos治疗日报的新闻和评级-在下面输入您的电子邮件地址，通过MarketBeat.com的免费每日电子邮件时事通讯接收对ALaunos治疗公司和相关公司的最新新闻和分析师评级的每日简要摘要。